- Home
- COLL vs BXC Comparison
COLL vs BXC Comparison
Compare COLL & BXC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- COLL
- BXC
- Stock Information
- Founded
- COLL 2002
- BXC 2004
- Country
- COLL United States
- BXC United States
- Employees
- COLL N/A
- BXC N/A
- Industry
- COLL Biotechnology: Pharmaceutical Preparations
- BXC Wholesale Distributors
- Sector
- COLL Health Care
- BXC Consumer Discretionary
- Exchange
- COLL Nasdaq
- BXC Nasdaq
- Market Cap
- COLL 1.1B
- BXC 936.7M
- IPO Year
- COLL 2015
- BXC 2004
- Fundamental
- Price
- COLL $29.58
- BXC $120.24
- Analyst Decision
- COLL Strong Buy
- BXC Strong Buy
- Analyst Count
- COLL 6
- BXC 3
- Target Price
- COLL $42.00
- BXC $135.67
- AVG Volume (30 Days)
- COLL 440.1K
- BXC 63.1K
- Earning Date
- COLL 11-07-2024
- BXC 10-29-2024
- Dividend Yield
- COLL N/A
- BXC N/A
- EPS Growth
- COLL 757.11
- BXC N/A
- EPS
- COLL 2.16
- BXC 3.41
- Revenue
- COLL $599,245,000.00
- BXC $2,954,424,000.00
- Revenue This Year
- COLL $13.02
- BXC N/A
- Revenue Next Year
- COLL $18.01
- BXC $4.71
- P/E Ratio
- COLL $13.68
- BXC $35.33
- Revenue Growth
- COLL 9.62
- BXC N/A
- 52 Week Low
- COLL $25.07
- BXC $84.43
- 52 Week High
- COLL $42.29
- BXC $132.67
- Technical
- Relative Strength Index (RSI)
- COLL 26.96
- BXC 59.57
- Support Level
- COLL $29.69
- BXC $121.64
- Resistance Level
- COLL $35.62
- BXC $127.46
- Average True Range (ATR)
- COLL 1.41
- BXC 5.15
- MACD
- COLL -0.39
- BXC 0.68
- Stochastic Oscillator
- COLL 6.36
- BXC 71.98
About COLL Collegium Pharmaceutical Inc.
Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of highly abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release and immediate-release formulations of tapentadol; Belbuca, and Symproic.
About BXC Bluelinx Holdings Inc.
BlueLinx Holdings Inc is engaged in the wholesale distribution of residential and commercial building products. Its business products are split into two categories: Structural products include items such as lumber, plywood, oriented strand board, rebar, and remesh and Specialty products include items such as engineered wood, siding, millwork, outdoor living, specialty lumber and panels, and industrial products. The company's operations are carried out throughout the United States.